PubMed Health⌕ Search

Biomedical subjects

S Wakefield

Publications and source records attributed to S Wakefield.

6 recordsLinked to original sources
PubMed1996

Pancreaticopleural fistula: a rare complication of chronic pancreatitis.

Pancreaticopleural fistula is an uncommon sequelae of pancreatitis. The condition is often elusive, as respiratory rather than abdominal symptoms usually predominate and the fistula can be difficult to demonstrate radiologically. Confirmation is by demonstrating a high amylase content in the pleural aspirate relative to the serum. About half the fistulae will close with conservative treatment but persistent or recurrent effusions, often associated with stenosis or disruption of the main pancreatic duct, are an indication for surgery. The long-term outcome is good in 80-95% of cases. We report five patients with pleural effusion of pancreatic origin due to pancreaticopleural fistula.

Adult↗
PubMed1994

A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

BACKGROUND: Both didanosine and zalcitabine are commonly used to treat patients with human immunodeficiency virus (HIV) infection who cannot tolerate zidovudine treatment or who have had disease progression despite it. The relative efficacy and safety of these second-line therapies are not well defined. METHODS: In this multicenter, open-label trial we randomly assigned 467 patients who previously received zidovudine and had 300 or fewer CD4 cells per cubic millimeter or a diagnosis of the acquired immunodeficiency syndrome (AIDS) to treatment with either didanosine (500 mg per day) or zalcitabine (2.25 mg per day). RESULTS: After a median follow-up of 16 months, disease progression or death occurred in 157 of 230 patients assigned to didanosine and 152 of 237 patients assigned to zalcitabine, for a relative risk of 0.93 for the zalcitabine group as compared with the didanosine group (P = 0.56), which decreased to 0.84 (P = 0.15) after adjustment for the CD4 count, Karnofsky score, and presence of AIDS at base line. There were 100 deaths in the didanosine group and 88 in the zalcitabine group, for a relative risk of 0.78 (P = 0.09) and an adjusted relative risk of 0.63 (P = 0.003). A majority of patients in each group (66 percent) had at least one adverse event during treatment (153 patients taking didanosine and 157 taking zalcitabine). Peripheral neuropathy and stomatitis occurred more often with zalcitabine and diarrhea and abdominal pain more frequently with didanosine. CONCLUSIONS: For patients with HIV infection who have not responded to treatment with zidovudine, zalcitabine is at least as efficacious as didanosine in delaying disease progression and death.

Acquired Immunodeficiency Syndrome↗
PubMed1985

Report of a case and further delineation of the SHORT syndrome.

We describe a boy with the manifestations of the SHORT syndrome: lipoatrophy, delayed speech development, minor facial anomalies, clinodactyly, and short stature. In addition, this boy had deafness, which was not previously reported in the SHORT syndrome.

Abnormalities, Multiple↗
PubMed1980

Abnormal cilia in Polynesians with bronchiectasis.

Bronchial or nasal ciliated epithelium from 13 patients with bronchiectasis (12 Polynesians and 1 European) was examined by electron microscopy. All cilia examined lacked dynein arams. In 2 patients, this was the only abnormality observed, but in the others, various ciliary abnormalities were present, including cilia with missing tubules, extra tubules, and misplaced tubules, as well as compound cilia, intracytoplasmic cilia, vesiculated cilia, and cilia with long winglike folds. In all of these patients pulmonary mucociliary transport rates were either absent or markedly reduced. It is suggested that these abnormalities were due to a mutation or group of mutations, which was the underlying cause of the bronchiectasis.

Adult↗